Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Gilead presents additional data on investigational antiviral remdesivir for the treatment of COVID-19.

Written by | 11 Jul 2020

Gilead Sciences, Inc. announced additional data on remdesivir, an investigational antiviral for the treatment of COVID-19, adding to the available body of knowledge on treatment outcomes with remdesivir…. read more.

Aldeyra Therapeutics development plans for an NDA for reproxalap in dry eye disease.

Written by | 8 Jul 2020

Aldeyra Therapeutics, Inc. announced development plans to support a New Drug Application (NDA) for the novel investigational reactive aldehyde species (RASP) inhibitor reproxalap in dry eye disease …. read more.

Regeneron initiates phase III trial of REGN-COV2 to treat and prevent Covid-19

Written by | 7 Jul 2020

Regeneron Pharmaceuticals, Inc. announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron’s investigational double antibody cocktail for the treatment and prevention of COVID-19 . A Phase III… read more.

BD launches portable, rapid point-of-care antigen test to detect SARS-CoV-2 in 15 minutes, dramatically expanding access to COVID-19 testing.

Written by | 7 Jul 2020

BD (Becton, Dickinson and Company) announced that the FDA granted Emergency Use Authorization (EUA) for a rapid, point-of-care, SARS-CoV-2 diagnostic test for use with its broadly available BD… read more.

European Commission approves Veklury a treatment for COVID-19 infection.- Gilead Sciences

Written by | 5 Jul 2020

Gilead Sciences, Inc.announced that the European Commission has granted conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. The conditional… read more.

Kevzara phase III U.S. trial in COVID-19 patients does not meet endpoints. Sanofi + Regeneron

Written by | 3 Jul 2020

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the . Phase III trial of Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary… read more.

Preliminary data shows that BNT 162b1 is safe and immunologically active in COVID-19.- Pfizer and BioNTech

Written by | 2 Jul 2020

Pfizer and BioNTech announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT 162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2. The BNT… read more.

Two phase I studies of INO 4800 report safety in COVID-19.- Inovio

Written by | 1 Jul 2020

Inovio has announced positive interim clinical data of INO 4800 vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase I clinical trial cohorts. In addition, INO… read more.

UK approves phase II/III study evaluating Yeliva in patients hospitalized with severe SARS-CoV-2 infection.- RedHill Biopharma

Written by | 30 Jun 2020

RedHill Biopharma Ltd. announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the Company’s Clinical Trial Authorization application to commence a Phase II/III study… read more.

CHMP recommends approval of Veklury for COVID-19 (novel coronavirus).- Gilead Sciences

Written by | 28 Jun 2020

The EU Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Veklury (remdesivir),… read more.

Fulcrum THerapeutics initiates phase III trial of losmapimod to treat COVID-19.

Written by | 25 Jun 2020

Fulcrum Therapeutics, Inc. announced that it received early notification from the FDA that the company may proceed with initiating a Phase III, randomized, double-blind, placebo-controlled trial of losmapimod… read more.

FDA grants emergency use authorisation for GenePro SARS-CoV-2 Test as diagnostic for COVID-19.- Gencurix

Written by | 25 Jun 2020

Gencurix has received FDA Emergency Use Authorization for its GenePro SARS-CoV-2 Test. It is the second RT-PCR test that Gencurix has launched following the first test assay, GenePro… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.